Quick answer
What is Pramlintide?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Pramlintide is a peptide, grouped on this site under Amylin and amylin receptor agonists, and the 12 research records kept here are 3 from studies in rats or mice, 7 from trials in people and 2 that do not state what kind of study it is.
The literature search returned 484 records. This site keeps 12 of them, which is 2.5 per cent of what came back.
What it is
This site puts it in the Amylin and amylin receptor agonists group.
A synthetic amylin analogue studied in the retrieved records as amylin replacement, with satiety and food intake endpoints.[1, 2]
Stated in the titles of the cited 2001 Current Pharmaceutical Design and 2005 Diabetologia papers.
What kind of records
Several of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 7 of 12 indexed records are interventional human trials by their own assigned publication type.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 472 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Current pharmaceutical design (2001). pmid:11472273
- Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia (2005). pmid:15843914